Chronic obstructive pulmonary disease and the risk of stroke

Annals of the American Thoracic Society

Volumn 14, Issue 5, 2017, Pages 754-765

  Morgan, Ann D ^a   Sharma, Chetna ^b   Rothnie, Kieran J ^a,c   Potts, James ^a   Smeeth, Liam ^c   Quint, Jennifer K ^a,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; EMBASE; HUMAN; INCIDENCE; MEDLINE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; COMPLICATION; META ANALYSIS;

HUMANS; INCIDENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SMOKING; STROKE;

EID: 85018955004     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201611-932SR     Document Type: Review

References (62)

1. Vanfleteren L E GW, Spruit MA, Groenen M, Gaffron S, van Empel V P M, Bruijnzeel P L B, Rutten E P A, Op't Roodt J, Wouters E F M, Franssen F M E. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:728-735.
2. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al.; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.
3. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099-2107.
4. Maclay JD, MacNee W. Assessment of cardiovascular comorbidity. In: Rabe KF, Wedzicha JA, Wouters EFM, editors. European Respiratory Society Monograph No. 59: COPD and comorbidity. Sheffield, UK: European Respiratory Society; 2013. pp. 28-49.
5. Man S F P, Van Eeden S, Sin DD. Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. Can J Cardiol 2012;28:653-661.
6. Roversi S, Roversi P, Spadafora G, Rossi R, Fabbri LM. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest 2014;44:93-102.
7. Sin DD, Man S F P. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.
8. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015;3:631-639.
9. de Miguel Díez J, Chancafe Morgan J, Jimeínez García R. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis 2013;8:305-312.
10. Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest 2013;144:1163-1178.
11. Rothnie KJ, Yan R, Smeeth L, Quint JK. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015;5:e007824.
12. Doehner W, Haeusler KG, Endres M, Anker SD, MacNee W, Lainscak M. Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease. Respir Med 2011;105:S12-S19.
13. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:956-962.
14. Yin L, Lensmar C, Ingelsson E, Bäck M. Differential association of chronic obstructive pulmonary disease with myocardial infarction and ischemic stroke in a nation-wide cohort. Int J Cardiol 2014;173:601-603.
15. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L.; PRISMA-P Group. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1-9.
16. Morgan AD, Sharma C, Rothnie KJ, Quint JK. Chronic obstructive pulmonary disease and the risk of stroke: a systematic review protocol. BMJ Open 2016;6:e011898.
17. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell.; Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014 [accessed 2016 March 4]. Available from: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
18. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
19. Antonelli-Incalzi R, Pedone C, Scarlata S, Battaglia S, Scichilone N, Forestiere F, Bellia V. Correlates of mortality in elderly COPD patients: focus on health-related quality of life. Respirology 2009;14:98-104.
20. Bentsen SB, Rust øen T, Miaskowski C. Prevalence and characteristics of pain in patients with chronic obstructive pulmonary disease compared to the Norwegian general population. J Pain 2011;12:539-545.
21. Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med 2012;106:249-256.
22. Cunningham TJ, Ford ES, Rolle IV, Wheaton AG, Croft JB. Associations of self-reported cigarette smoking with chronic obstructive pulmonary disease and co-morbid chronic conditions in the United States. COPD 2015;12:276-286.
23. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada: cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70.
24. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, Frances JF, Lozano PV, Belloín-Cano J.; CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis 2012;7:679-686.
25. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009;4:337-349.
26. García-Olmos L, Alberquilla A, Ayala V, García-Sagredo P, Morales L, Carmona M, de Tena-Dávila MJ, Pascual M, Muñoz A, Salvador CH, et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. BMC Fam Pract 2013;14:11.
27. Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Morbidity and mortality associated with the restrictive spirometric pattern: a longitudinal study. Thorax 2010;65:499-504.
28. Jo YS, Choi SM, Lee J, Park YS, Lee SM, Yim JJ, Yoo CG, Kim YW, Han SK, Lee CH. The relationship between chronic obstructive pulmonary disease and comorbidities: a cross-sectional study using data from KNHANES 2010-2012. Respir Med 2015;109:96-104.
29. Lin P-J, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med 2010;104:697-704.
30. Lindberg A, Larsson LG, Rönmark E, Lundbäck B. Co-morbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function. COPD 2011;8:421-428.
31. Loípez Varela MV, Montes de Oca M, Halbert R, Muiño A, Taílamo C, Peírez-Padilla R, Jardim JR, Valdivia G, PertuzeíJ, Menezes A.; PLATINO Team. Comorbidities and health status in individuals with and without COPD in five Latin American cities: the PLATINO study. Arch Bronconeumol 2013;49:468-474.
32. Mapel DW, Picchi MA, Hurley JS, Frost FJ, Petersen HV, Mapel VM, Coultas DB. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest 2000;117(5, Suppl 2):346S-353S.
33. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005;2:35-41.
34. Miniati M, Monti S, Pavlickova I, Bottai M. Survival in COPD: impact of lung dysfunction and comorbidities. Medicine (Baltimore) 2014;93:e76.
35. Nagorni-Obradovic LM, Vukovic DS. The prevalence of COPD co-morbidities in Serbia: results of a national survey. NPJ Prim Care Respir Med 2014;24:14008.
36. Pleasants RA, Ohar JA, Croft JB, Liu Y, Kraft M, Mannino DM, Donohue JF, Herrick HL. Chronic obstructive pulmonary disease and asthma: patient characteristics and health impairment. COPD 2014;11:256-266.
37. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010;25:253-260.
38. Schnell K, Weiss CO, Lee T, Krishnan JA, Leff B, Wolff JL, Boyd C. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012;12:26.
39. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068-2075.
40. van Manen JG, Bindels PJ, IJzermans CJ, van der Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001;54:287-293.
41. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640-2646.
42. Knuiman MW, James AL, Divitini ML, Ryan G, Bartholomew HC, Musk AW. Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study. Ann Epidemiol 1999;9:297-306.
43. Lin HW, Chung CL, Lin YS, Yu CM, Lee CN, Bien MY. Inhaled pharmacotherapy and stroke risk in patients with chronic obstructive pulmonary disease: a nationwide population based study using twostage approach. PLoS One 2015;10:e0130102.
44. Portegies M L P, Lahousse L, Joos GF, Hofman A, Koudstaal PJ, Stricker BH, Brusselle GG, Ikram MA. Chronic obstructive pulmonary disease and the risk of stroke: the Rotterdam Study. Am J Respir Crit Care Med 2016;193:251-258.
45. Soderholm M, Inghammar M, Hedblad B, Egesten A, Engstrom G. Incidence of stroke and stroke subtypes in chronic obstructive pulmonary disease. Eur J Epidemiol 2016;31:159-168.
46. Austin V, Crack PJ, Bozinovski S, Miller AA, Vlahos R. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci (Lond) 2016;130:1039-1050.
47. Dodd JW, Chung AW, van den Broek MD, BarrickTR, Charlton RA, Jones PW. Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. Am J Respir Crit Care Med 2012;186:240-245.
48. Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebrovascular disease: a comprehensive review. Respir Med 2015;109:1371-1380.
49. Arboix A, Morcillo C, Garća-Eroles L, Oliveres M, Massons J, Targa C. Different vascular risk factor profiles in ischemic stroke subtypes: a study from the "Sagrat Cor Hospital of Barcelona Stroke Registry." Acta Neurol Scand 2000;102:264-270.
50. Arboix A. Cardiovascular risk factors for acute stroke: risk profiles in the different subtypes of ischemic stroke. World J Clin Cases 2015;3:418-429.
51. Windsor CL, Herrett E, Smeeth L, Quint J. The association between exacerbation frequency and stroke risk, in patients with COPD: a matched case-control study [abstract]. Thorax 2014;69(Suppl 2):A214.
52. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-1097.
53. Pujades-Rodriguez M, George J, Shah AD, Rapsomaniki E, Denaxas S, West R, Smeeth L, Timmis A, Hemingway H. Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1 937 360 people in England: lifetime risks and implications for risk prediction. Int J Epidemiol 2015;44:129-141.
54. Gulsvik AK, Gulsvik A, Skovlund E, Thelle DS, MoweíM, Humerfelt S, Wyller TB. The association between lung function and fatal stroke in a community followed for 4 decades. J Epidemiol Community Health 2012;66:1030-1036.
55. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-715, discussion 715-716.
56. Hozawa A, Billings JL, Shahar E, Ohira T, Rosamond WD, Folsom AR. Lung function and ischemic stroke incidence: the Atherosclerosis Risk in Communities Study. Chest 2006;130:1642-1649.
57. Strachan DP. Ventilatory function as a predictor of fatal stroke. BMJ 1991;302:84-87.
58. Truelsen T, Prescott E, Lange P, Schnohr P, Boysen G. Lung function and risk of fatal and non-fatal stroke: the Copenhagen City Heart Study. Int J Epidemiol 2001;30:145-151.
59. Wannamethee SG, Shaper AG, Ebrahim S. Respiratory function and risk of stroke. Stroke 1995;26:2004-2010.
60. Dow L, Ebrahim S. Commentary: Lung function and risk of fatal and non-fatal stroke: the Copenhagen City Heart Study. Int J Epidemiol 2001;30:152-153.
61. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol 2010;6:681-694.
62. Piñol-Ripoll G, de la Puerta I, Santos S, Purroy F, Mostacero E. Chronic bronchitis and acute infections as new risk factors for ischemic stroke and the lack of protection offered by the influenza vaccination. Cerebrovasc Dis 2008;26:339-347.